E. Freireich

Publications741
h-index100
Citations38,928
Highly Influential Citations746
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Kantarjian
  • 4,842 Publications • 223,916 Citations
  • S. O'brien
  • 1,860 Publications • 88,190 Citations
  • M. Keating
  • 1,416 Publications • 81,260 Citations
  • J. Cortes
  • 3,075 Publications • 110,731 Citations
  • Publications
  • Influence
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.
View on PubMed
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
TLDR
This data indicates a relationship between leukopenia and the presence of infection in patients with a history of acute leukemia and indicates the need for further research into this relationship.
View on PubMed
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
TLDR
The data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in theLeukemogenic process.
View on PubMed
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
TLDR
Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.
View on PubMed
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
TLDR
Patients who underwent allogeneic SCT as postremission therapy had longer survival than patients who achieved remission and received no additional therapy or patients who underwentAllogeneic or autologous SCTAs salvage therapy as salvage therapy.
View on PubMed
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia
TLDR
The current analysis updated the long‐term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD) program, with a median follow‐up time of 63 months.
View on Wiley
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
TLDR
The high rate of very long-term PFS in patients with IGHV-M after FCR argues for the continued use of chemoimmunotherapy in this patient subgroup outside clinical trials; alternative strategies may be preferred in patients as well, to limit long- term toxicity.
View on PubMed
Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia
TLDR
Comparing MS patients with analogous AML patients and comparing their clinical outcomes addressed the question of whether patients with nonleukemic myeloid sarcoma and those with acuteMyeloid leukemia have similar responses to anti‐AML treatment.
View on Wiley
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
TLDR
The prognosis of most patients with acute myeloid leukemia (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months).
View on PubMed
The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy
TLDR
The study was stopped after analysis of the remission times of 21 pairs of patients, since patients maintained on placebo were treated with 6-MP when relapse occurred, and overall survival was not significantly different for the two treatment programs.
View via Publisher
...
...